Rezo Therapeutics Funding Round

11/17/2022

Venture Equity

$78,000,000

Series A

The company will use the funds to Advance Pipeline of Precision Therapeutics Based on Groundbreaking Integrated Disease Network Mapping Platform.

Private & Independent

Biopharmaceutical

Cottage Place 320 City Road
London England, EC1V 2NZ
UK

Undisclosed

Rezo is tackling some of the most difficult challenges in medicine by mapping and therapeutically targeting networks that go awry in disease. Starting with genomic data, Rezo integrates distinct, unbiased technologies coupled with artificial intelligence to identify targets and therapies. Based on pioneering work from the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco, our mission is to break the mold in traditional drug development through the convergence of distinct scientific disciplines and insights from academia and industry. Rezo's proprietary platform is applicable across a broad range of diseases. The initial focus of Rezo is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships.